The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

Authors :: Cook, Gordon
Royle, Kara‐Louise
O'Connor, Sheila
Cairns, David A.
Ashcroft, A. John
Williams, Cathy D.
Hockaday, Anna
Cavenagh, Jamie D.
Snowden, John A.
Ademokun, Debo
Tholouli, Eleni
Andrews, Vivienne E.
Jenner, Matthew
Parrish, Christopher
Yong, Kwee
Cavet, Jim
Hunter, Hannah
Bird, Jenny M.
Pratt, Guy
Drayson, Mark T.
Brown, Julia M.
Morris, Treen C. M.
Source :: British Journal of Haematology
Publication Year :: 2019
Publisher :: John Wiley and Sons Inc., 2019.
Abstract: Summary The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high‐risk. The effect of cytogenetics on time to progression (TTP) and overall survival was investigated. At 76 months median follow‐up, ASCT improved TTP compared to cyclophosphamide (19 months (95% confidence interval [95% CI] 16–26) vs. 11 months (9–12), hazard ratio [HR]: 0·40, 95% CI: 0·29–0·56, P

Tools